Hydroponics to partner with Israel’s BOL Pharma

The Hydroponics Company Ltd, a star performer since listing in the surging medical cannabis sector, is entering into a partnership with BOL Pharma.

BOL Pharma is one of Israel’s leading medicinal cannabis producers with an extensive portfolio of products targeted for specific clinical applications.

The Hydroponics Company has now executed on its strategy of a dual import or domestic supply of medicinal cannabis.

The company also remains on track to complete its domestic R&D and growing facility.

The next steps will include BOL Pharma initiating a clinical trial with Canndeo, expanding its multiple indications into Australia.

Canndeo, with Hydroponics as the parent organization, also recently signed an agreement with Endoca B.V. to distribute medicinal cannabis products into Australia.

Endoca is one of Europe’s most highly respected suppliers of GMP (Good Manufacturing Practice) certified medicinal cannabis, with sales exceeding €50 million per annum.

BOL Pharma has agreed to supply all products required for an initial clinical trial with the long term view of providing products for additional clinical trials that are targeting to take place during 2018.